Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 10:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 263 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: First Intervention (14 days) Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Brain Imaging Techniques That Predict Antidepressant Responsiveness

NCT00909155
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Venlafaxine ERT, Fluoxetine
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 3, 2018 · Synced Oct 10, 2026, 10:20 AM EDT
Completed Not applicable Interventional

Investigating Trunk Control in Young Children With Down Syndrome

NCT03544840
View directory record Official record
Conditions
Down Syndrome, Gross Motor Development Delay
Interventions
Physical Therapy Home Program
Other
Lead sponsor
Texas Woman's University
Other
Eligibility
6 Months to 24 Months
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2019 · Synced Oct 10, 2026, 10:20 AM EDT
Recruiting Phase 2 Interventional

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

NCT06031688
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Lymphoscintigraphy, Magnetic Resonance Imaging, Ramucirumab, Tepotinib
Procedure · Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Minutes and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
278
States / cities
Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 232 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 10, 2026, 10:20 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Metabolic Wellness and CGM

NCT06790472
View directory record Official record
Conditions
Cardiometabolic Risk Factors
Interventions
Online Lifestyle Intervention, Continuous Glucose Monitoring
Behavioral · Device
Lead sponsor
David Kerr
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 10, 2026, 10:20 AM EDT
Completed Not applicable Interventional Results available

Using MOST to Optimize an Intervention to Increase COVID-19 Testing for Frontline Essential Workers

NCT05139927
View directory record Official record
Conditions
COVID-19, COVID-19 Testing
Interventions
Motivational interviewing (MI) counseling, Text messages (TMs) and quiz questions (QQs), Peer education, Access to COVID testing
Behavioral
Lead sponsor
New York University
Other
Eligibility
18 Years to 70 Years
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 10, 2026, 10:20 AM EDT
Terminated Phase 1 Interventional

Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease

NCT01677572
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 90 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
32
States / cities
Tucson, Arizona • Laguna Hills, California • Lomita, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 10, 2026, 10:20 AM EDT
Completed Not applicable Interventional

Immune Modulation by Enhanced vs Standard Prehabilitation Program Before Major Surgery

NCT04498208
View directory record Official record
Conditions
Surgery, Immune System and Related Disorders, Preoperative Care, Gastrointestinal Disease, Urological Disease, Gynecologic Disease, Thoracic Diseases
Interventions
Physical Prehabilitation, Stress Reduction Prehabilitation, Cognitive Prehabilitation, Nutrition Prehabilitation
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 10, 2026, 10:20 AM EDT
Completed Not applicable Interventional Results available

Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection

NCT02241187
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
PEGPH20, Cetuximab, DW & DCE-MRI, blood draws
Drug · Device · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 10, 2026, 10:20 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Community Pharmacy-Based Prescription Drug Monitoring Program Opioid Risk Assessment Tool

NCT05706311
View directory record Official record
Conditions
Opioid Abuse, Prescription Opioid Abuse
Interventions
Clinical Decision Support Tool (Moderate Risk), Clinical Decision Support Tool (High Risk), Standard of Care
Behavioral · Other
Lead sponsor
University of Utah
Other
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Cincinnati, Ohio • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 10, 2026, 10:20 AM EDT
Completed Not applicable Interventional Results available

Clareon PanOptix Pro vs. Clareon PanOptix - Study B

NCT06401551
View directory record Official record
Conditions
Aphakia, Presbyopia
Interventions
CPO Pro IOL, CPO IOL, Cataract Surgery
Device · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
22 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
8
States / cities
Torrance, California • Bloomfield Hills, Michigan • Kansas City, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 10, 2026, 10:20 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder

NCT04818086
View directory record Official record
Conditions
Drug Interaction, Analgesics, Opioid Use Disorder
Interventions
Lemborexant, Placebo, Buprenorphine-naloxone
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Oct 10, 2026, 10:20 AM EDT
Completed Phase 4 Interventional Results available

A Text Messaging Program for Smokers in Primary Care

NCT03174158
View directory record Official record
Conditions
Smoking Cessation
Interventions
Mailed nicotine replacement therapy, Text messaging, Brief advice
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 10, 2026, 10:20 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma

NCT00691652
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, clofarabine, DNA methylation analysis, gene expression analysis, microarray analysis, polymerase chain reaction, high performance liquid chromatography, laboratory biomarker analysis
Biological · Drug · Genetic + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 89 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 10, 2026, 10:20 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis

NCT01287364
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
ciclesonide hydrofluoroalkane (HFA) nasal aerosol, mometasone nasal inhalation
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
6
States / cities
Mission Viejo, California • San Diego, California • North Dartmouth, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2012 · Synced Oct 10, 2026, 10:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Autism Intervention Research Network for Behavioral Health (AIR-B II): Deployment Into Elementary Schools

NCT01724047
View directory record Official record
Conditions
Autism
Interventions
Playground Intervention, STAT Intervention
Behavioral
Lead sponsor
Health Resources and Services Administration (HRSA)
Federal
Eligibility
4 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
3
States / cities
Los Angeles, California • Rochester, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 10, 2026, 10:20 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

NCT03674411
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia, Relapsed Large Cell Lymphoma, Mantle Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Lymphoplasmacytic Lymphoma
Interventions
Fludarabine (FLU), Cyclophosphamide (CY), Total Body Irradiation (TBI), Tacrolimus (Tac), Mycophenolate Mofetil (MMF), Granulocyte Colony-Stimulating Factor (G-CSF), Busulfan (BU), Melphalan, MGTA 456 Infusion
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 10, 2026, 10:20 AM EDT
Terminated Phase 2 Interventional Results available

Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors

NCT02372409
View directory record Official record
Conditions
Glioma, Pilocytic Astrocytoma, Anaplastic Astrocytoma, Glioblastoma, Mixed Oligoastrocytoma, Mixed Glioma, Oligodendroglioma, Optic Glioma, Astrocytoma
Interventions
MRI-guided laser ablation, Doxorubicin, Etoposide, Dynamic contrast-enhanced (DCE) MRI, Dynamic susceptibility contrast (DSC) MRI
Device · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
3 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 10, 2026, 10:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fasting ENHANCE Pilot Study

NCT05732935
View directory record Official record
Conditions
Overweight and Obesity, Time Restricted Feeding, Alzheimer Disease
Interventions
Time Restricted Eating intervention, Successful Aging Comparison Group (LEARN)
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
65 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 10, 2026, 10:20 AM EDT
Completed Phase 2 Interventional Results available

Stereotactic Body Radiation With Nelfinavir for Oligometastases

NCT01728779
View directory record Official record
Conditions
Oligometastases
Interventions
Nelfinavir, Stereotactic Body Radiation (SBRT)
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 10, 2026, 10:20 AM EDT
Completed Not applicable Interventional

Benefits of Continuous Glucose Monitoring With GEM Lifestyle Modification for Adults With Type 2 Diabetes

NCT03207893
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GEM lifestyle modification & continuous glucose monitoring, Routine Care
Behavioral · Other
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 10, 2026, 10:20 AM EDT
Completed Phase 2 Interventional

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission

NCT00002768
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, busulfan, cytarabine, etoposide, methotrexate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
15 Years to 69 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2009
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • Paterson, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Oct 10, 2026, 10:20 AM EDT
Recruiting Phase 1Phase 2 Interventional

Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease

NCT07346157
View directory record Official record
Conditions
Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma Recurrent
Interventions
Liothyronine (L-T3), Bevacizumab, Irinotecan, Temozolomide (TMZ)
Drug
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
1 Year to 25 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
San Francisco, California • Washington D.C., District of Columbia • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 10, 2026, 10:20 AM EDT
Active, not recruiting Not applicable Interventional

Optimizing a mHealth Physical Activity Intervention With Mindful Awareness Lessons in Breast Cancer Survivors

NCT05931874
View directory record Official record
Conditions
Breast Cancer
Interventions
Core Intervention, E-Coach, Buddy, General Mindfulness Training, MVPA-Specific Mindfulness Training
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 10, 2026, 10:20 AM EDT
Recruiting Phase 2 Interventional

Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

NCT06627244
View directory record Official record
Conditions
Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver
Interventions
Tebentafusp, TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization
Drug · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 10, 2026, 10:20 AM EDT